Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 昊海生科
Other Market Stock Code688366
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameHaohai Biotec
Stock Code06826
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於研發、生產及銷售醫用可吸收生物材料,產品應用於骨科、防黏連及止血、眼科和創面護理及組織填充等治療領域。
Listing Date2015-04-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市長寧區虹橋路1386號文廣大廈23樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Website3healthcare.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 59.00 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2015-04-20 to 2015-04-23
Global Offering Shares40,000,000 shares
HK Public Offer Shares (Initial)4,000,000 shares (10.0%)
Public Offer Lots (Initial)40,000lots (Pool A20,000lots,Pool B20,000lots)
International Placing Shares (Initial)36,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO160,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share4.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,360,000,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 661.6M
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣183.6百萬元
Period-End Cash Balance人民幣181.3百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201220132014
Revenue 303,065401,088515,940
Cost of sales -50,313-54,836-65,883
Gross profit 252,752346,252450,057
Other income and gains, net 10,83523,67730,764
Selling and distribution expenses -72,537-143,315-187,191
Administrative expenses -36,272-34,221-48,960
Profit before tax 133,432166,467215,616
Income tax expense -19,490-24,946-32,034
Profit for the year 113,942141,521183,582
Profit attributable to owners 113,942141,521183,582
Balance Sheet
Item 201220132014
Cash and cash equivalents 160,814197,137181,341
Trade and bills receivables 29,48043,82062,443
Inventories 40,86442,60476,364
Total current assets 245,287297,448347,355
Total assets 448,037621,178751,903
Total current liabilities 54,70276,128139,239
Total liabilities 58,98090,600157,743
Total equity 389,057530,578594,160
Equity attributable to owners 389,057530,578594,160
Cash Flow Statement
Item 201220132014
Net cash from operating activities 118,420146,906141,993
Net cash from investing activities -84,293-111,249-88,151
Net cash from financing activities 00-70,320
Net increase in cash 34,12735,657-16,478
Depreciation of PP&E 11,5599,56220,917
Amortisation of intangible assets 1,3782,3891,186
Purchase of PP&E -64,626-124,361-93,544
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 58.4
First Day OpenHK$ 54.0
First Day Change-1.01%
First Day Volume18649000.0
First Day Turnover1065410000.0
Use of Proceeds
1、約25%或約563百萬港元,將用于建設上海利康瑞的新生產線,包括動物源纖維蛋白封閉劑產品及醫用生物材料的新生產設施,以應付對產品不斷增長的需求; 2、約25%或約563百萬港元,將用于選擇性收購專注于我們目標治療領域內具高增長潛能產品及對我們現有產品組合具互補性產品的合適生物醫藥或醫用生物材料公司或資產。截至最后實際可行日期,我們尚未物色到任何可予收購的目標; 3、約18%的所得款項凈額,或約405百萬港元,將用于購買新生產設備,以及翻新及改造昊海生物設施; 4、約13%或約293百萬港元,將用于資助在研產品(包括溫敏性幾丁糖產品及新一代交聯透明質酸鈉產品)的研發活動及臨床應用; 5、約9%或約203百萬港元,將用于招聘更多營銷及銷售人員以擴大我們的銷售及營銷網絡,及將我們成功開發的在研產品進行商業投產,以及提升營銷及促銷活動水平; 6、約10%或約225百萬港元,將用作營運資金及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (3)
UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225
Joint Lead Managers (3)
UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Dragon Billion China Master Fund 193,697,000 HKD — 2.05% — 6 months 2015-10-30
2 方圆投资管理(香港)有限公司 232,460,000 HKD — 2.46% — 6 months 2015-10-30

Directors & Management

PositionChinese nameEnglish Name
Chairman侯永泰—
Company Secretary黃平、趙明璟—
No director data available.

Major Shareholders

Major Shareholders & Holdings蔣偉及游捷(配偶)合共持有75,600,000股,佔全球發售後本公司全部股本約47.25%;樓國梁持有10,000,000股,佔約6.25%。
About this page

This page shows Haohai Biotec (06826) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect